NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
March 28, 2026 — Ezalife reports strong early sales and $1.6M institutional investment for its Button Huggie® feeding tube device as its StartEngine equity crowdfunding campaign nears close on April 6.
March 27, 2026 — Auddia announces 1-for-7.7 reverse stock split effective April 2026 to meet Nasdaq listing requirements. AI audio technology company aims to boost stock price above $1 minimum.
March 27, 2026 — Forian Inc. reports 50% revenue growth for 2025, achieves Adjusted EBITDA targets, and receives acquisition proposal from CEO-led consortium. Life sciences data analytics leader expands market presence.
March 27, 2026 — Lixte Biotech advances precision oncology with LB-100 therapy and Liora Technologies partnership. Learn how this innovation enhances cancer treatment efficacy while reducing side effects through data integration.
March 27, 2026 — UGI Electric files a $17.3 million annual rate increase request with Pennsylvania regulators to fund system upgrades, impacting 63,000 customers' bills and service reliability.
March 27, 2026 — LaFleur Minerals files NI 43-101 report for Swanson Gold Deposit PEA, showing 65% IRR and C$101M NPV, targeting gold production restart in Québec's Abitibi Belt.
March 27, 2026 — B2i Digital partners with Centri Capital Conference 2026 at Nasdaq, connecting 50+ growth companies in AI, tech, and healthcare with 500+ investors. Learn about the agenda and registration.
March 27, 2026 — Aptevo's mipletamig shows 86% clinical benefit rate in AML trial with no cytokine release syndrome. New data suggests potential to enhance frontline treatment for older patients.
March 27, 2026 — Ethema Health names James Poage as CFO to enhance SEC filings and drive growth in substance use disorder treatment. Learn how this impacts financial strategy.
March 27, 2026 — LaFleur Minerals releases positive PEA results for its gold project, with a low-CapEx mine-to-mill strategy aiming for spring production. Learn about the economic model and investor insights.
March 27, 2026 — Trilogy Metals advances its high-grade Arctic copper deposit in Alaska with federal backing and improved permitting. Key developments include regulatory support and a $35.6M investment.
March 27, 2026 — American Fusion Inc. (OTC: AMFN) achieves SEC milestone, with Form 10-12G effective May 2026, boosting transparency and supporting uplisting plans post-merger with Kepler Fusion Technologies.
March 27, 2026 — Sigyn Therapeutics unveils CardioDialysis, a single-device technology to reduce heart attacks and strokes by clearing inflammatory molecules, deployable on existing dialysis machines for wider access.
March 27, 2026 — BYD's European EV sales triple in early 2026, challenging traditional automakers like Ferrari. Chinese brands gain market share, reshaping Europe's electric vehicle landscape and green energy trends.
March 27, 2026 — Iran conflict disrupts energy markets, boosting long-term prospects for electric vehicles (EVs) and companies like Rivian. Analysis explores the crisis as a turning point for transport.
March 27, 2026 — Canamera Energy Metals advances rare earth exploration in Brazil, tapping into world's second-largest reserves. Promising results from Turvolândia project highlight potential to diversify global supply chains for critical minerals.
March 27, 2026 — Trilogy Metals announces 2026 AGM and details on its Upper Kobuk Mineral Projects in Alaska, targeting copper and cobalt production. Learn about key partnerships and exploration updates.
March 27, 2026 — A2Z Cust2Mate extends $20M share buyback through 2026, reflecting confidence in undervalued stock. Company's AI smart carts transform retail with in-cart payment & personalized offers.
March 27, 2026 — SKYX Platforms reports record 2025 revenue of $92M, expands retail partnerships with Home Depot and Walmart, and collaborates with NVIDIA AI, driving smart home innovation.
March 27, 2026 — Lantern Pharma receives FDA clearance for Phase 1 pediatric trial of STAR-001 targeting brain cancers. AI-driven drug development shows promise for aggressive pediatric malignancies with unmet needs.